Your Location：
Home >
Browse articles >
Resveratrol Regulates STIM1 to Inhibit Atherosclerosis
Updated：2024-01-04
Previous|Next

    • Resveratrol Regulates STIM1 to Inhibit Atherosclerosis

    • WU Zhi-xue , ZHANG Ren , LIN Rui-shan , XU Jin-wen , YAN Fu-man , LIU Hai-mei
    • Chinese Journal of Experimental Traditional Medical Formulae Vol. 23, Issue 15, Pages: 148-153(2017)

    • DOI： 10.13422/j.cnki.syfjx.2017150148     

      CLC：

    Scan QR Code

  •  
  •  

  • Full Text(HTML)

  • Publication Info

  • Metrics

Sections
icon
The trial reading is over, you can activate your VIP account to continue reading.
Deactivate >
icon
The trial reading is over. You can log in to your account, go to the personal center, purchase VIP membership, and read the full text.
Already a VIP member?
Log in >

27

Views

45

Downloads

3

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Effect of Resveratrol in Regulating TRPC1/STIM1-mediated SOCC to Inhibit Atherosclerosis
Iron Homeostasis Imbalance Promotes Atherosclerosis and Therapeutic Mechanisms of Traditional Chinese Medicine
Mechanism of Huoxin Pills in Stabilizing Atherosclerotic Vulnerable Plaque Based on Network Pharmacology and Metabolomics
Differentiation and Treatment of Vulnerable Atherosclerotic Plaque Based on "Collateral Disease" Theory
Mechanism of Danlou Tablets in Ameliorating Hepatic Lipid Deposition by Regulating circCRIM1/miR-342-3p/SOX6-mediated Fatty Acid Synthesis

Related Author

LIU Hai-mei
YAN Fu-man
ZHOU Le-quan
LIU Na
WANG Maohong
XIONG Jianhua
ZHANG Hao
YAN Xiaohong

Related Institution

Jiangxi University of Chinese Medicine
The Affiliated Hospital of Jiangxi University of Chinese Medicine
School of Chinese Materia Medica，Guangzhou University of Chinese Medicine
Baiyunshan Pharmaceutical General Factory， Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Guangzhou Caizhilin Pharmaceutical Co. Ltd.